BEYANG Therapeutics uses its ExCEED AI-powered molecular design platform to discover and develop differentiated small-molecule therapeutics. Its lead programs include BT01001, a non-invasive eye drop candidate for retinal diseases, and BT01002, a next-generation Menin inhibitor designed to overcome resistance in acute leukemia. The company plans to advance these programs through clinical development and expand its global R&D capabilities. BEYANG is positioning its platform-driven approach to accelerate drug discovery timelines and generate globally competitive assets. The recent Series A financing is intended to fund those development and expansion plans.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2026